Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Mirum Pharmaceuticals. The associated price target was raised to $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including the strong commercial performance of Mirum Pharmaceuticals’ flagship product, LIVMARLI. The company reported significant revenue growth in the second quarter of 2025, with LIVMARLI sales increasing substantially year-over-year, driven by its adoption in treating Alagille syndrome and progressive familial intrahepatic cholestasis, particularly in the U.S. This robust performance prompted the management to raise their revenue guidance for 2025, indicating confidence in continued growth.
Furthermore, Mirum’s strategic moves, such as securing reimbursement for LIVMARLI in Japan and launching a tablet formulation in the U.S., are expected to contribute positively to future revenues. The company’s engagement with the patient-provider community to expand genetic testing could potentially increase the market size. Additionally, growth in Mirum’s bile acid portfolio, including the newly approved Ctexli, adds to the positive outlook, supporting the Buy rating with a new price target of $80 per share.